ARS Pharmaceuticals (SPRY) Intangibles (2023 - 2026)

ARS Pharmaceuticals has disclosed Intangibles across 4 years of filings, most recently posting $14.2 million for Q1 2026.

• Intangibles for Q1 2026 came in at $14.2 million, up 95.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.2 million (up 95.77% YoY), and the FY2025 annual result was $14.5 million, up 96.07% from the prior year.
• Intangibles came in at $14.2 million for Q1 2026 at ARS Pharmaceuticals, down from $14.5 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $14.7 million in Q3 2025 to a low of $188000.0 in Q2 2025.
• The 4-year median for Intangibles is $7.3 million (2024), against an average of $6.7 million.
• Peak annual rise in Intangibles reached 1271.4% in 2025, while the deepest fall reached 57.85% in 2025.
• ARS Pharmaceuticals' Intangibles stood at $617000.0 in 2023, then jumped by 1094.65% to $7.4 million in 2024, then soared by 96.07% to $14.5 million in 2025, then slipped by 1.91% to $14.2 million in 2026.
• The last three Intangibles figures came in at $14.2 million (Q1 2026), $14.5 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.